French company Servier and Belgium's Galapagos have entered into a multi-year strategic alliance to discover and develop new small molecule therapies for cancer, building on their existing relationship in the field of osteoarthritis.
French company Servier and Belgium's Galapagos have entered into a multi-year strategic alliance to discover and develop new small molecule therapies for cancer, building on their existing relationship in the field of osteoarthritis.
Under the latest agreement, Galapagos will receive research access payments of €2 million from Servier. Galapagos is also eligible for...
Create an account to read this article
Already a subscriber?
Japan has emerged as a global leader in the development of new drugs for the rare cancer angiosarcoma, reflecting its rapidly ageing population and the limitations of current therapies.
Pharma companies like Sarepta, Replimune and Capricor made gains on Wall Street after news broke that the FDA Center for Biologics Evaluation and Research director Vinay Prasad is leaving.
GSK is sticking to its guns on its forecasts for Blenrep and the firm’s total sales in 2031 despite concerns about the antibody-drug conjugate’s approvability in the US.
The BRUIN CLL-314 trial was designed to show noninferiority, but the p-value indicated a favorable result for Jaypirca in both the pre-treated and intent-to-treat populations.
Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.
In an interview, chief commercial officer Tolga Tanguler gave some ideas of what to expect as the company prepares to launch the drug for ATTR-CM in Europe.
The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.
